Clinical trial · Interventional
A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)
A Multicenter Trial to Evaluate 18F-FDG Uptake by PET in Patients With Advanced Pancreatic Adenocarcinoma as an Early Indicator of Drug Activity
NCT01050283CI-TRIAL-00018664terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will determine whether \[18F\]-fluorodeoxyglucose-positron emission tomography (FDG-PET) can be used to screen for the activity of novel pancreatic cancer treatments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Comparator: [18F]-FDG PET/CT and Volumetric CT | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- \[18F\]-FDG-PET/CT (Computed Tomography) Imaging
- interventionNames
- Procedure: Comparator: [18F]-FDG PET/CT and Volumetric CT
Primary outcomes (1)
- measure
- Association of changes in FDG uptake with overall survival (OS)
- timeFrame
- Week 3 and at least 7 months after the last patient is treated
Secondary outcomes (2)
- measure
- Association of metabolic response with OS
- timeFrame
- Baseline, Week 3, and at least 7 months after the last patient is treated
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Patient has a diagnosis of Stage IV pancreatic adenocarcinoma with distant metastases * Patient is scheduled to receive standard chemotherapy containing gemcitabine * Patient has not received prior systemic therapy for advanced pancreatic adenocarcinoma * Patient must be available for periodic blood sampling, study-related assessments, and management at the treating institution Exclusion Criteria: * Patient has had open abdominal surgery within 6 weeks of the screening visit * Patient has had radiotherapy to the thorax, abdomen, or pelvis within 6 months of the screening visit * Patient has an active infection, inflammation, or unresolved bowel obstruction * Patient has poorly controlled diabetes
References
Publications (0)
Data not yet available
No reference posted for this study.